Literature DB >> 12231563

Contribution of double-stranded RNA-activated protein kinase toward antiproliferative actions of heparin on vascular smooth muscle cells.

Rekha C Patel1, Indhira Handy, Chandrashekhar V Patel.   

Abstract

OBJECTIVE: The proliferation of vascular smooth muscle cells (VSMCs) in blood vessels after endothelial injury contributes to the onset of atherosclerosis. Heparin is a potent antiproliferative agent for VSMCs in vivo and in vitro. Although heparin has shown promise in suppressing VSMC proliferation after invasive procedures in laboratory animals, the mechanism of its antiproliferative actions is largely unknown. Here, we present evidence for the first time that the antiproliferative action of heparin is in part mediated by its ability to activate double-stranded RNA-activated protein kinase (PKR), an interferon-induced protein kinase. METHODS AND
RESULTS: We have analyzed the VSMC proliferation by cell-cycle analysis and correlated it to the kinase activity of PKR in the presence of heparin. Heparin treatment of VSMCs results in activation of PKR by direct binding and results in a block in G1- to S-phase transition. PKR-null cells are largely insensitive to the antiproliferative actions of heparin, and inhibition of PKR in VSMCs results in a partial abrogation of the antiproliferative effects of heparin.
CONCLUSIONS: These results invoke the involvement of novel PKR-dependent regulatory pathways in mediating the antiproliferative actions of heparin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12231563     DOI: 10.1161/01.atv.0000028817.20351.fe

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  8 in total

Review 1.  Molecular regulation of contractile smooth muscle cell phenotype: implications for vascular tissue engineering.

Authors:  Jeffrey A Beamish; Ping He; Kandice Kottke-Marchant; Roger E Marchant
Journal:  Tissue Eng Part B Rev       Date:  2010-10       Impact factor: 6.389

2.  Identification of the heparin-binding domains of the interferon-induced protein kinase, PKR.

Authors:  Stephen Fasciano; Brian Hutchins; Indhira Handy; Rekha C Patel
Journal:  FEBS J       Date:  2005-03       Impact factor: 5.542

3.  Regulation of vascular smooth muscle proliferation by heparin: inhibition of cyclin-dependent kinase 2 activity by p27(kip1).

Authors:  Stephen Fasciano; Rekha C Patel; Indhira Handy; Chandrashekhar V Patel
Journal:  J Biol Chem       Date:  2005-02-24       Impact factor: 5.157

4.  The effects of heparin releasing hydrogels on vascular smooth muscle cell phenotype.

Authors:  Jeffrey A Beamish; Leah C Geyer; Nada A Haq-Siddiqi; Kandice Kottke-Marchant; Roger E Marchant
Journal:  Biomaterials       Date:  2009-08-26       Impact factor: 12.479

5.  The mechanisms of nadroparin-mediated inhibition of proliferation of two human lung cancer cell lines.

Authors:  Y Carmazzi; M Iorio; C Armani; S Cianchetti; F Raggi; T Neri; C Cordazzo; S Petrini; R Vanacore; F Bogazzi; P Paggiaro; A Celi
Journal:  Cell Prolif       Date:  2012-12       Impact factor: 6.831

6.  The chemotherapeutic drug 5-fluorouracil promotes PKR-mediated apoptosis in a p53-independent manner in colon and breast cancer cells.

Authors:  María Angel García; Esther Carrasco; Margarita Aguilera; Pablo Alvarez; Carmen Rivas; Joaquin María Campos; Jose Carlos Prados; Miguel Angel Calleja; Mariano Esteban; Juan Antonio Marchal; Antonia Aránega
Journal:  PLoS One       Date:  2011-08-24       Impact factor: 3.240

7.  Interaction of human tRNA-dihydrouridine synthase-2 with interferon-induced protein kinase PKR.

Authors:  Megan Mittelstadt; Andrea Frump; Tuanh Khuu; Vennece Fowlkes; Indhira Handy; Chandrashekhar V Patel; Rekha C Patel
Journal:  Nucleic Acids Res       Date:  2007-12-20       Impact factor: 16.971

8.  Neutrophil TLR4 and PKR are targets of breast cancer cell glycosaminoglycans and effectors of glycosaminoglycan-induced APRIL secretion.

Authors:  Uilst Bat-Erdene; Eric Quan; Kelvin Chan; Brianna-Marie Lee; Wejdan Matook; Ki-Young Lee; Jesusa L Rosales
Journal:  Oncogenesis       Date:  2018-06-15       Impact factor: 7.485

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.